GEN - Genetic Engineering and Biotechnology News21h
From Tools to Trials: Editing Therapy Companies Pivot to Development
A pair of privately-held developers of editing-based therapies have some successes to show for their recent efforts to ...
Gene therapy loses luster as investors eye quicker returns from weight-loss drugs
By Deena Beasley (Reuters) -Gene therapy, with its offer of a possible cure for rare diseases like sickle cell, is losing ...
Editas Medicine Announces Chief Financial Officer Transition
Erick J. Lucera to Step Down as CFO to pursue another opportunitySenior Vice President of Finance Amy Parison Appointed CFOCAMBRIDGE, Mass., ...
Editas Medicine, Inc.: Editas Medicine Announces Chief Financial Officer Transition
Erick J. Lucera to Step Down as CFO to pursue another opportunity Senior Vice President of Finance Amy Parison Appointed CFO CAMBRIDGE, Mass., March 20, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc.
Inc427h
How Endiya Partners Sharpened Its AI, Deeptech Thesis Over The Past Decade
Endiya actively assists portfolio companies with product rollouts, customer acquisition hiring, and preparing for future ...
Can Healthcare Stocks Keep Outperforming the Market?
How GLP-1 drugs, regulatory concerns, and more factors are shaping the sector. Plus, 3 undervalued healthcare stocks.
pharmaphorum16h
Vertex buys diabetes cell therapy rival ViaCyte for $320m
Vertex has doubled down on cell-based therapies for type 1 diabetes (T1D), buying ViaCyte in a $320 million deal that it says will accelerate development of its own candidate VX-880. The deal has ...
IPPMEDIA16h
Regulator fears oil spills as pipeline systems take shape
WITH the construction of the East African Crude Oil Pipeline (EACOP) nearing completion, oil storage tanks already in place and oil fields allocated for the project, stakeholders in the region are ...